Tanshinone IIA, a Component of the Self-made Xiao-Yin Decoction, Ameliorates Psoriasis by Inhibiting IL-17/IL-23 and PTGS2/NF-κB/AP-1 Pathways

Overview

Journal Skin Res Technol

Specialty Biomedical Engineering

Date 2024 Jan 29

PMID 38284293

Authors

Lei Fu

Meijiao Li

Peng Wang

Lang Chen

Jianqiu Huang

Hui Zhang

Affiliations

Soon will be listed here.

Abstract

Background: Psoriasis is a persistent inflammatory dermatological disorder. Tanshinone IIA (tan-IIA) is a biologically active compound in the self-made Xiao-Yin decoction (SMXYD) and exhibits diverse biological properties, such as anti-proliferative and anti-inflammatory effects. The objective of this investigation was to assess the potential of tan-IIA as a therapeutic agent against psoriasis.

Methods: Network pharmacology was employed to ascertain the active constituents and potential pathways associated with SMXYD and psoriasis. We conducted CCK-8, qRT-PCR, and western blotting to assess the proliferation of HaCaT keratinocytes and the expression of IL-17/IL-23 and PTGS2/NF-κB/AP-1 pathways. Additionally, we used H&E staining, western blotting, and ELISA to evaluate the therapeutic effects and signaling pathways of tan-IIA in psoriasis-like mice induced by imiquimod (IMQ).

Results: Network pharmacology analysis identified eight hub compounds. The Th17/IL-17 signaling was found to be a potential therapeutic pathway of SMXYD against psoriasis, with JUN (AP-1) as the core molecule. Next, PTGS2 was selected as the target of tan-IIA against psoriasis using network pharmacology analysis. Molecular docking showed a high affinity between PTGS2 and tan-IIA. Tan-IIA treatment attenuated M-5-induced hyperproliferation and inflammation in HaCaT keratinocytes. Additionally, Tan-IIA downregulated the PTGS2/NF-κB/AP-1 pathway in HaCaT keratinocytes. In the IMQ-induced psoriasis-like mouse, tan-IIA significantly reduced the severity of skin lesions and downregulated the PTGS2/NF-κB/AP-1 pathway. Moreover, the combination of methotrexate (MTX) and tan-IIA further inhibited the IL-17/IL-23 and PTGS2/NF-κB/AP-1 pathways.

Conclusion: The administration of tan-IIA has shown a positive effect on psoriasis by inhibiting the IL-17/IL-23 and PTGS2/NF-κB/AP-1 pathways. The findings suggest that it has promising qualities that make it a potential candidate for the development of future anti-psoriatic agents.

Citing Articles

Tanshinone IIA, a component of the self-made Xiao-Yin decoction, ameliorates psoriasis by inhibiting IL-17/IL-23 and PTGS2/NF-κB/AP-1 pathways.

Fu L, Li M, Wang P, Chen L, Huang J, Zhang H Skin Res Technol. 2024; 30(2):e13577.

PMID: 38284293 PMC: 10823401. DOI: 10.1111/srt.13577.

References

Meng Z, Si C, Teng S, Yu X, Li H . Tanshinone IIA inhibits lipopolysaccharide‑induced inflammatory responses through the TLR4/TAK1/NF‑κB signaling pathway in vascular smooth muscle cells. Int J Mol Med. 2019; 43(4):1847-1858. DOI: 10.3892/ijmm.2019.4100. View

Kauffman C, Aria N, Toichi E, McCormick T, Cooper K, Gottlieb A . A phase I study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12 p40 antibody in subjects with plaque psoriasis. J Invest Dermatol. 2004; 123(6):1037-44. DOI: 10.1111/j.0022-202X.2004.23448.x. View

Subedi L, Gaire B . Tanshinone IIA: A phytochemical as a promising drug candidate for neurodegenerative diseases. Pharmacol Res. 2021; 169:105661. DOI: 10.1016/j.phrs.2021.105661. View

Cargill M, Schrodi S, Chang M, Garcia V, Brandon R, Callis K . A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. Am J Hum Genet. 2007; 80(2):273-90. PMC: 1785338. DOI: 10.1086/511051. View

Fleischmann R, Schiff M, van der Heijde D, Ramos-Remus C, Spindler A, Stanislav M . Baricitinib, Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Disease-Modifying Antirheumatic Drug Treatment. Arthritis Rheumatol. 2016; 69(3):506-517. PMC: 5347954. DOI: 10.1002/art.39953. View

Aluganti Narasimhulu C, Fernandez-Ruiz I, Selvarajan K, Jiang X, Sengupta B, Riad A . Atherosclerosis--do we know enough already to prevent it?. Curr Opin Pharmacol. 2016; 27:92-102. DOI: 10.1016/j.coph.2016.02.006. View

Reich K, Papp K, Blauvelt A, Tyring S, Sinclair R, Thaci D . Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials. Lancet. 2017; 390(10091):276-288. DOI: 10.1016/S0140-6736(17)31279-5. View

Novoszel P, Holcmann M, Stulnig G, De Sa Fernandes C, Zyulina V, Borek I . Psoriatic skin inflammation is promoted by c-Jun/AP-1-dependent CCL2 and IL-23 expression in dendritic cells. EMBO Mol Med. 2021; 13(4):e12409. PMC: 8033525. DOI: 10.15252/emmm.202012409. View

Ma J, Feng S, Ai D, Liu Y, Yang X . D-Pinitol Ameliorates Imiquimod-Induced PsoriasisLike Skin Inflammation in a Mouse Model via the NF-κB Pathway. J Environ Pathol Toxicol Oncol. 2019; 38(3):285-295. DOI: 10.1615/JEnvironPatholToxicolOncol.2019030782. View

10.

Li T, Gao S, Han W, Gao Z, Wei Y, Wu G . Potential effects and mechanisms of Chinese herbal medicine in the treatment of psoriasis. J Ethnopharmacol. 2022; 294:115275. DOI: 10.1016/j.jep.2022.115275. View

11.

Langley R, Krueger G, Griffiths C . Psoriasis: epidemiology, clinical features, and quality of life. Ann Rheum Dis. 2005; 64 Suppl 2:ii18-23. PMC: 1766861. DOI: 10.1136/ard.2004.033217. View

12.

van der Fits L, Mourits S, Voerman J, Kant M, Boon L, Laman J . Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis. J Immunol. 2009; 182(9):5836-45. DOI: 10.4049/jimmunol.0802999. View

13.

Nair R, Callis Duffin K, Helms C, Ding J, Stuart P, Goldgar D . Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways. Nat Genet. 2009; 41(2):199-204. PMC: 2745122. DOI: 10.1038/ng.311. View

14.

Fu L, Li M, Wang P, Chen L, Huang J, Zhang H . Tanshinone IIA, a component of the self-made Xiao-Yin decoction, ameliorates psoriasis by inhibiting IL-17/IL-23 and PTGS2/NF-κB/AP-1 pathways. Skin Res Technol. 2024; 30(2):e13577. PMC: 10823401. DOI: 10.1111/srt.13577. View

15.

Fang C, Xie L, Liu C, Fu C, Ye W, Liu H . Tanshinone IIA improves hypoxic ischemic encephalopathy through TLR‑4‑mediated NF‑κB signal pathway. Mol Med Rep. 2018; 18(2):1899-1908. PMC: 6072156. DOI: 10.3892/mmr.2018.9227. View

16.

Griffiths C, Barker J . Pathogenesis and clinical features of psoriasis. Lancet. 2007; 370(9583):263-271. DOI: 10.1016/S0140-6736(07)61128-3. View

17.

Arasa J, Terencio M, Andres R, Marin-Castejon A, Valcuende-Cavero F, Paya M . Defective Induction of COX-2 Expression by Psoriatic Fibroblasts Promotes Pro-inflammatory Activation of Macrophages. Front Immunol. 2019; 10:536. PMC: 6448046. DOI: 10.3389/fimmu.2019.00536. View

18.

Nair R, Stuart P, Nistor I, Hiremagalore R, Chia N, Jenisch S . Sequence and haplotype analysis supports HLA-C as the psoriasis susceptibility 1 gene. Am J Hum Genet. 2006; 78(5):827-851. PMC: 1474031. DOI: 10.1086/503821. View

19.

Yan J, Yang X, Han D, Feng J . Tanshinone IIA attenuates experimental autoimmune encephalomyelitis in rats. Mol Med Rep. 2016; 14(2):1601-9. PMC: 4940100. DOI: 10.3892/mmr.2016.5431. View

20.

Kumar S, Han J, Li T, Qureshi A . Obesity, waist circumference, weight change and the risk of psoriasis in US women. J Eur Acad Dermatol Venereol. 2012; 27(10):1293-8. PMC: 4179884. DOI: 10.1111/jdv.12001. View